Quizartinib Significantly Increases Survival For AML Patients With FLT3 Mutations

The FLT3-ITD tandem duplication mutation is the most common mutation in AML and this mutation renders the FLT3 enzyme constitutively active, sending a constant growth signal to malignant myeloid cells.

The presence of this mutation results in a poor prognosis and treatment resistance, which prevents most patients from getting life saving stem cell transplants. When this occurs, survival times are usually measured in weeks.

Quizartinib (AC220) is a small molecule inhibitor that targets the FLT3-ITD mutation.

Results from a recent phase II study of quizartinib in adult AML patients who had relapsed or not responded to second-line therapies or stem cell transplantation resulted in a total objective response rate of 79%.

In this study, the median survival time was 22.9 weeks for patients with confirmed FLT3-ITD mutations and 25.6 weeks in patients without.

However, the overall survival was significantly increased when patients proceeded to allogeneic stem cell transplant.

Among the patients with confirmed FLT3-ITD mutations that received allogeneic stem cell transplants, the median overall survival was 33.3 weeks with 36% of patients still alive more than 60 weeks to date, compared with 17.7 weeks for patients not undergoing transplantation.

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation.

 

NEW! AML-MDS POP NOW AVAILABLE FOR DOWNLOAD


Comments

  1. Your style is really unique compared to other folks I’ve read stuff from. I appreciate you for posting when you’ve got the opportunity, Guess I’ll just book mark this blog.

    • Thank you Garsoniera. We focus on posting information that patient`s can utilize in their treatments. Please feel free to request a post.
      All the best and take care,

      The CTOAM Team

Speak Your Mind

*